Use of External Specialist Organizations, CROs and Scientific Advisory Boards
First written in FY2016. 6 of 8 entries say "Restated". Latest entry: FY2026.
16 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The company has established a close partnership with a major CRO specializing in the clinical development of anticancer drugs. It has also formed a scientific advisory board (SAB) comprising scientists expected to contribute to its research and development, including through their extensive experience in the clinical development of anticancer drugs. SAB meetings have been held regularly twice a year since the board was established in March 2002, for information sharing and discussion covering research and development as a whole.」
The company continues to operate its research and development activities using a major CRO and the SAB, with the SAB meeting twice a year. - FY2024RestatedAnnual report
「The company has held SAB meetings chaired by this individual twice a year on a regular basis since the SAB was established in March 2002, exchanging information and discussing research and development matters generally.」
The company continues to work with major CROs and use the SAB, holding SAB meetings twice a year. - FY2023-Q3AdvancedAnnual report
「As part of preparations to start the Phase 3 clinical trial of CBP501, the company entered into an agreement with a CRO (contract research organization), increasing advance payments by ¥379.263 million.」
As part of preparations to start the Phase 3 trial of CBP501, the company made concrete progress in using an external specialist organization by entering into an agreement with a CRO. - FY2022RestatedAnnual report
「In clinical development, the company enables flexible clinical trial operations through close alliances with major global CROs with extensive experience in developing anticancer drugs.」
The company continues to operate its research and development activities with a small workforce supplemented by alliances with major CROs and the Scientific Advisory Board. - FY2021RestatedAnnual report
「In clinical development, the company enables flexible clinical trial operations through close alliances with major global CROs with extensive experience in developing anticancer drugs.」
The company continues to operate its research and development activities with a small workforce supplemented by major CROs, external experts and the Scientific Advisory Board. - FY2020RestatedAnnual report
「In clinical development, the company has established close alliances with major global CROs with extensive experience in developing anticancer drugs. The company has also established a Scientific Advisory Board (SAB) comprising scientists expected to contribute to its research and development, including through their extensive experience in the clinical development of anticancer drugs.」
The company continues to operate its research and development activities with a small workforce supplemented by major CROs and the SAB. - FY2017RestatedAnnual report
「In clinical development, the company enables flexible clinical trial operations through close alliances with major global CROs with extensive experience in developing anticancer drugs. The company has also established a Scientific Advisory Board (SAB) comprising scientists expected to contribute to its research and development, including through their extensive experience in the clinical development of anticancer drugs.」
The company continues to operate its research and development activities with a small workforce supplemented by CROs, external experts and the SAB. - FY2016First statedAnnual report
「The company uses external specialists, including CROs, and a scientific advisory group that align with its development strategy.」
The company supplements its small workforce by using external specialists, CROs and a Scientific Advisory Board at each stage of research and development.